Lance Baldo, M.D., Chief Medical Officer, Adaptive Biotechnologies Sponsored Content by Adaptive Biotechnologies
Advertisement
Articles by Lance Baldo, M.D., Chief Medical Officer, Adaptive Biotechnologies Sponsored Content by Adaptive Biotechnologies
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5